February 03, 2025
3 min watch
Save
VIDEO: Study results ‘solidifying’ role of blinatumomab treatment in pediatric ALL
SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.
“This is really solidifying the role of blinatumomab [Blincyto, Amgen] across the age spectrum in combination with chemotherapy for front-line treatment of B-ALL,” Luskin, part of the adult leukemia program at Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School, told Healio.
Reference:
- Rau RE, et al. Abstract 1. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Luskin reports no relevant financial disclosures.
Read more about